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Antiretroviral Update: New Drugs on the Block
Following a virtual renaissance in HIV therapeutics in the mid 1990’s, the later part of the decade wit-
nessed a sputtering of the HIV treatment pipeline.  Since 1998 only three new antiretroviral agents
have come to market, amprenavir (Agenerase), lopinavir-ritonavir (Kaletra) and tenofovir (Viread).  In
addition, re-formulations of existing drugs have been approved including the fixed dose combination
of ZDV, 3TC and abacavir (Trizavir) and enteric coated ddI (Videx EC), bringing the current tally of
approved antiretroviral agents to 19. This article will review aspects of these newer drugs and dis-
cuss their role in HAART of treatment naïve and experienced patients.  A complete listing of avail-
able antiretroviral agents, doses, and common side effects is provided in HIV 101 of this issue. 
Lopinavir/Ritonavir (Kaletra)
One of the most exciting new antiretroviral agents in some time is the fixed combination of lopinavir
and ritonavir (LPV/RTV). This combination exploits the ability of RTV to greatly enhance levels of
another protease inhibitor (PI), in this case LPV.  Each capsule of the drug contains 133 mg of LPV
and 33 mg of RTV. As three (3) capsules of the combination are taken twice a day, each dose con-
tains 400 mg of LPV and
100 mg of RTV.  LPV/RTV
has been studied in treat-
ment naïve and antiretro-
viral experienced subjects
in combination with other
agents.  Results of a piv-
otal study comparing d4T
and 3TC in combination
with either LPV/RTV ver-
sus nelfinavir, involving
over 650 antiretroviral
naïve subjects, were
recently reported.1 After
60 weeks, 64% of the sub-
jects in the LPV/RTV arm
had an HIV viral load
below 50 copies/mL com-
pared to 52% in the nelfi-
navir arm (p=0.001).
Virologic failure was
reported in only 1% of
the LPV/RTV subjects
verses 9% of the nelfi-
navir-assigned subjects.2
Strangely, none of the 40
subjects failing LPV/RTV had genotypic or phenotypic resistance to protease inhibitors while 37% of
the 84 nelfinavir assigned subjects with virologic failure did have mutations associated with
decreased susceptibility to PIs. Even more unexpected was the virtual absence of the 3TC resis-
tance-associated mutation at codon 184 in the
LPV/RTV arm compared to the nelfinavir arm.
Clearly, this is not a business-as-usual PI.
In PI- and NRTI- experienced but NNRTI-naïve
subjects, LPV/RTV has been studied in combina-
tion with an NNRTI.  In this context, the combina-
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Figure 1: Phase II Multiple ARV-Experienced Patients: Virologic
Response to LPV/TRV with Respect to Baseline Genotype
*Selected from 11 mutations associated with reduced susceptibility to LPV 
(protease amino acid positions 10, 20, 24, 46, 53, 54, 63, 71, 82, 84 & 90)
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tion of LPV/RTV and the NNRTI was very
effective at reducing viral load below
detectable limits. However, the effect of
adding an agent from a new class (i.e.
NNRTI) makes pinning all this success on
LPV/RTV difficult. Characterization of the
resistance profile of LPV/RTV, as discussed
above, has been hampered by the small
numbers of subjects failing the drug and a
lack of resistance mutations detected in
those who have. Failure to respond to
LPV/RTV in patients with pre-existing resis-
tance mutations has been described and
response to the drug is dependent on the
number of mutations present at baseline.
These data indicate that multiple mutations
are required to reduce susceptibility to
LPV/RTV (see figure 1).
The attraction of LPV/RTV as a component
of a salvage regimen is obvious. Here is a
drug that appears to be slowed down only
by multiple mutations, is active against virus
with protease inhibitors resistance mutations
and can be given as 3 pills twice a day.
‘Voila!,’ the Abbott scientists must have pro-
claimed when they realized what they creat-
ed. This strength, though, has turned out to
be the drug’s weakness.  Some clinicians
view LPV/RTV as a drug to reserve for sal-
vage – a sort of ace in the hole. However,
there is a compelling argument to use the
agent earlier. The ease of administration,
potency and probable high threshold for
resistance accumulation position the agent
as an attractive element of initial therapy. A
major concern regarding this approach is
the lack of understanding of the conse-
quences of LPV/RTV failure and the implica-
tion for future treatment response. At this
time, clinicians have to judge for themselves
where to place this agent until more data are
available to address the outstanding ques-
tions.
Drug-drug interactions of LPV/RTV are what
would be expected of a ritonavir (RTV) -con-
taining regimen. Additionally, data suggest a
decrease in plasma levels when the agent is
combined with an NNRTI. Therefore, the
dose of LPV/RTV should, in most cases, be
4 capsules BID when efavirenz or nevirap-
ine are also used. The drug is best absorbed
with food.
Adverse effects include mostly gastrointesti-
nal problems. There have been reports of
lower extremity edema with LPV/RTV not
due to deep vein thrombosis or right-sided
heart failure. LPV/RTV does lead to pertur-
bations of lipids, and therefore it would be
surprising if it did not produce those body
shape changes associated with the pro-
tease inhibitors class.
As in the case with RTV, there are storage
issues relevant to correctional facilities,
especially those located in regions where it
can get very hot. Unlike RTV, LPV/RTV does
not need to be refrigerated if used within 2
months and can be stored at temperatures
up to 77° F (up to room temperature).
However, if the temperature is higher, as is
the case in most of the cell blocks in North
Carolina in July and August, the product
breaks down quickly. If refrigerated, both
LPV and RTV remain stable until the expira-
tion date on the manufacturer's label. These
storage requirements can pose challenges
for systems where drugs are provided ‘keep
on person’ (KOP) and where it gets hot as
Georgia asphalt in the summer.
Tenofovir (Viread)
This newest addition to the antiretroviral war
chest is a little pill that is taken once a day.
Tenofovir is a nucleotide analogue, which
means the agent is already in the nucleotide
form that nucleoside analogues are convert-
ed to in the body. The drug has been
approved for initial and salvage treatment of
HIV infection despite the fact that there are
few data regarding use of the drug as initial
therapy.  The manufacturers have conduct-
ed trials in HIV-therapy experienced patients
and have demonstrated moderate potency
of the drug.  In one study 189 subjects, who
were receiving antiretroviral therapy for a
minimum of 8 weeks but continued to have
detectable HIV viral loads, were randomized
to receive intensification with three different
doses of tenofovir or placebo. At 48 weeks,
subjects assigned to receive the 300 mg
dose of tenofovir had a modest, but mean-
ingful, reduction in viral load (80% or 0.62
log).3 A larger study involving over 550 sub-
jects compared the addition of 300 mg dose
of tenofovir versus placebo, again in treat-
ment-experienced patients with detectable
HIV viremia.  At 24 weeks, when all patients
rolled over to active drug, 19% of the 368
tenofovir-assigned subjects had a viral load
below 50 copies/mL compared to 1% of the
182 subjects randomized to placebo.4 These
results are to be formally presented at the
Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC) in
December. 
An international trial of 600 naïve subjects in
which tenofovir, as part of a combination
including efavirenz and 3TC, is being com-
pared to a regimen of d4T, efavirenz, and
3TC, is ongoing.
Tenofovir susceptibility is reduced in the
presence of multiple nucleoside analogue-
associated mutations, particularly when the
M41L and  L210W mutations are present.
Multiple thymidine analogue mutations or
TAMs (M41L, L210W D67N, K70R, T215Y/F
among others) is associated with decreased
efficacy of tenofovir. The K65R mutation and
multi-drug resistance mutations such as the
T69S confer resistance to the drug.  
The side effect profile of the drug, to date,
appears favorable. Unlike related drugs
such as adefovir and cidofovir, tenofovir
does not seem to cause renal insufficiency
to any great extent. Nausea, vomiting and
diarrhea have been reported with use of the
drug; however, it remains unclear if tenofovir
contributes to metabolic complications of
therapy such as fat redistribution or hyper-
lactatemia. In animal studies there have
been problems with bone mineralization
prompting the inclusion of bone density
evaluations in Gilead sponsored studies of
tenofovir in humans. Post-marketing surveil-
lance of side effects will be required to fully
characterize the adverse effect profile of this
drug. To date, there are no data indicating
that bone density is a problem in people.
High fat meals increase the bioavailability of
the drug, therefore, it is recommended teno-
fovir be taken with a meal.
Where tenofovir will fit in the grand scheme
of treatment is not clear at present. This
easy to take agent may become a "cherry on
top" drug, added to regimens that are com-
monly perceived to need a bit of a boost,
such as in the use of triple nucleosides in
patients with high viral loads, in salvage reg-
imens in multi-drug experienced patients
and for intensification of a newly failing regi-
men. The drug may also become part of a
once a day regimen along with other exis-
tent and forthcoming once a day therapies -
provided meal requirements do not conflict.
Amprenavir (Agenerase)
Originally dismissed as a ‘me-too’ protease
inhibitor, amprenavir does stand a little (and
I mean a little) apart from the pack. Studies
of antiretroviral naïve and experienced
patients demonstrate that amprenavir is
effective as a component of a three or more
drug regimen and, by virtue of a somewhat
disparate pattern of resistance develop-
ment, may have some unique applications.
For example, one of the biggest selling
points for this hefty protease inhibitors
(weighing in at 16 pills per day) is that it has
a novel pattern of resistance which would
indicate relatively limited cross resistance to
other PIs. The initial mutation seen in
patients failing amprenavir is at codon 50,
which is relatively unique. Subsequently
generated mutations, however, do overlap
with other PIs (for a constantly updated list
of HIV resistance mutations go to
www.iasusa.org and click on ‘Drug
Resistance Mutations’: see Resources and
Websites). Likewise, this overlap of muta-
tions, such as the I84V mutation in particu-
lar, would predict that virus resistant to indi-
navir and ritonavir would be less susceptible
to amprenavir. 
However, in a pivotal trial of nucleoside
reverse transcriptase inhibitor (NRTI) expe-
rienced but protease inhibitor (PI) naïve sub-
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Dear HEPP News Readers,
As this issue of HEPP News went to press, we were busy at the 25th Conference on Correctional
Health Care (NCCHC) in Albuquerque, New Mexico.  We started the conference on a great note
with the annual HEPP preconference symposium. This year’s symposium was entitled: "Bridging
the Gap: Getting High Risk Patients into Treatment," a topic that went with the theme of our
Aug./Sept. 2001 HEPP News. We had fabulous presentations by many well-known correctional
doctors, including our own Chief Editor, Anne De Groot, who gave presentations on TB in cor-
rections and on the issues facing women inmates  with HIV.  Deputy Editor Joe Bick also report-
ed on issues facing transgendered patients and their HIV treatment and prevention: Dr. Michael
Wong gave a presentation on Hepatitis C in corrections; Joe Paris, another HEPP Editor, spoke
about the outbreak of Hepatitis B in the Georgia DOC earlier this year; Rob Lyerla, from the CDC,
discussed the state of Hepatitis B in corrections nationwide; and Dr. Eric Avery, spoke on mental
health treatment in HIV-positive patients in corrections. We appreciate the time and effort our pre-
senters gave to make the symposium a success.
Many other HEPP "celebrities" were seen at the conference, including Dr. David Thomas, Dr.
Dean Rieger, Dr. Ted Hammett and a great dancer, HEPP advisor Ned Heltzer. We all attended
important presentations on health care in prison, especially as it relates to HIV and Hepatitis. Next
month’s issue will include a "Rapid Report" section with conference updates. We will focus on the
presentations on women, Hepatitis B and C, and HIV as they relate to corrections.
In this issue, Associate Editor David Wohl provides a comprehensive drug update, looking at the
three newest drugs that have become part of HAART: amprenavir, lopinavir/ritonavir, and the lat-
est FDA approved drug, tenofovir.  HIV101 complements the main article, providing an updated
table describing all of the antiretroviral medications now available. This month’s spotlight was
written by The Corrections Connection’s, Michelle Gaseau, who interviewed Robyn Gershon from
Columbia University’s school of public health.  Gershon spearheaded a study on postexposure
prophylaxis (PEP) in corrections, the first study of its kind. The HEPPigram supplements the inter-
view by providing updated PEP recommendations for various types of exposures to HIV.
After reading this issue, health care providers should understand the basics of the new antiretro-
viral medications, including dosing and drug interactions; readers should also understand what
an occupational exposure to HIV is, which drug regimens to use in the case of an occupational
exposure to HIV, and what documentation is recommended.
Next month’s issue will focus on opportunistic infections and recommendations for treating those
infections presented by Dr. Joe Bick.  We encourage our readers to submit summaries from any
NCCHC presentation or any other topics!
Sincerely,
Rebecca Nerenberg, 
Managing Editor, HEPP News
Letter from the Editor
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4jects pitting a triple drug therapy of two
NRTIs and amprenavir against two NRTIs
coupled with indinavir, there appeared to be
no clear difference between these protease
inhibitors in reducing viral load. At 24 weeks
43% of the amprenavir assigned patients
had HIV viral loads below 400 copies/mL
compared to 53% of the indinavir assigned
subjects.5 This trend favoring indinavir was
not statistically significant.  Adverse events,
however, were more common in the ampre-
navir arm and were related to gastrointesti-
nal intolerance and rash. 
Furthermore, in the most rigorous studies of
amprenavir in NNRTI- and PI- experienced
subjects, the role of the drug was obfuscated
by an unforeseen drug-drug interaction with
efavirenz, which was included as part of the
experimental salvage regimens.  After a dis-
mal showing for amprenavir (only a quarter
of subjects receiving amprenavir, efavirenz
and abacavir had viral load below 400
copies/mL) it became apparent that
efavirenz substantially lowers amprenavir
levels in the blood.  
Amprenavir appears more likely to produce
rash than other drugs of this class and this
can cause confusion when combined with a
NNRTI or abacavir. Stevens-Johnson
Syndrome is reported in as many as 1% of
patients taking this drug. Gastrointestinal
adverse effects are common as is circumoral
paresthesia (tingling around the mouth). A
suggestion that this is a protease inhibitor
that is less likely to cause dyslipidemia and
body shape changes has become somewhat
less relevant as the drug has been coupled
with lower dose RTV in an effort to reduce
the pill burden of amprenavir. RTV at higher
doses has been demonstrated to increase
triglycerides and cholesterol and has been
linked to truncal fat accumulation. Whether
these effects are dose dependent remains
unclear.  Each 150 mg amprenavir pill con-
tains 109 IU of vitamin E. Therefore, supple-
mental vitamin E should be avoided.
When used without RTV, the dose of ampre-
navir is 1200 mg BID. The drug can be taken
with or without food but not with a high fat
meal. With RTV the dose can be reduced as
RTV acts to increase plasma levels of the
drug. Several dose regimens have been
examined including amprenavir-600 mg plus
RTV-100 mg both BID, amprenavir-600 mg
plus RTV-200 mg both BID and amprenavir-
1200 mg plus RTV-200 mg QD. While these
regimens are not on the package insert, they
are commonly used in clinics. Special atten-
tion must be paid to drug interactions. As
mentioned, when the drug is coupled with
efavirenz a reduction in plasma levels of
amprenavir occurs. Some clinicians recom-
mend that when efavirenz or nevirapine is
added to amprenavir that 200 mg of RTV and
600 mg of amprenavir be used.
Capitalizing on a somewhat disparate
sequence of resistance evolution to ampre-
navir, the manufacturers have tried to posi-
tion the drug as a first PI-failure option. This
application of the drug has not caught on in
many places.  It is likely that this has much to
do with the extraordinary pill burden and the
availability of other options.  Hope, however,
may be on the horizon. The manufacturers of
amprenavir have developed a pro-drug for-
mulation, GW433908, affectionately referred
to as ‘908’. This drug will likely require 2 pills
twice a day. Clinical study of this agent is
underway but approval is likely to be one
year away. 
New Formulations of
Older Agents
By now most clinicians have become familiar
with the fixed dose combination of ZDV, 3TC
and abacavir (Trizavir). This one pill BID reg-
imen has the efficacy and tolerability that
would be expected with exposure to these
compounds. In addition, an enteric-coated
formulation of ddI has been approved. The
original formulation of ddI contained an
antacid to buffer against degradation of the
drug in the acid or the stomach. The new for-
mulation uses a protective coating instead.
The result is a normal sized capsule that can
be swallowed instead of chewed, less gas-
trointestinal disturbance caused by the buffer
and reduced drug interactions with agents
requiring stomach acidity for absorption.  The
drug still needs to be taken on an empty
stomach. The toxicity is expected to mirror
that of the older formulation, but with better
palatability, one wonders whether we will see
more people actually taking the drug as rec-
ommended and, therefore, more of the toxic-
ity we associate with ddI. 
New Regimens
The array of available agents for treatment of
HIV infection has led clinicians to develop
diverse therapeutic strategies. For instance,
patients initiating antiretroviral therapy can
now be treated with a PI-based, PI-sparing,
NNRTI-based or triple NRTI regimen, among
others. Reassuringly, it appears there are no
major differences in antiretroviral effective-
ness across popular treatment strategies.
John A. Bartlett from Duke University recent-
ly published an analysis of the results of 23
HIV treatment trials in which antiretroviral
naïve subjects received dual NRTIs and
either a PI, an NNRTI, or a third NRTI, and
found that these three approaches were not
significantly different in their ability to drive
HIV viral load levels below 50 copies/mL.6
With generally similar efficacy expected with
these treatment strategies, consideration of
regimen composition now focuses on tailor-
ing therapy to patient-specific issues of
adherence and tolerability. Pill count, fre-
quency of dosing, drug-drug interactions and
side effect tolerance can now be considered
when devising a regimen - recasting associ-
ations of HAART with handfuls of multicol-
ored pills that make people sick.   
Salvage therapy has also evolved and fre-
quently involves inventive, and sometimes
ragtag, collections of agents - often inspired
as much by results of resistance testing and
pharmacologic boosting as by wishful think-
ing. Yet, salvage therapy continues to pro-
vide diminishing returns with high long-term
failure rates seen in most every study. As
persons with HIV infection live longer and
cycle through antiretrovirals, there is a need
for new agents that are effective against
viruses that have accumulated multiple resis-
tance mutations.
Conclusion
More drugs, more choices. The question
remains, though, ‘How, short of a cure, can
new drugs continue to be developed to meet
the needs of an increasingly treatment expe-
rienced and socially complex HIV positive
population?"  With the rate of new HIV infec-
tions continuing to be on the order of
40,000+ per year and HAART failure rates
high, there remains, unfortunately, a market
for new antiretrovirals. Industry’s most recent
responses to this challenge were described
in this article.  While none of these agents
offer what most would consider a major
advance in the treatment of HIV, they do
complement the palette of available drugs
and provide an opportunity for creative
options in initial and salvage treatment.
Antiretroviral Update...
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*Speaker’s Bureaus: GSK, Gilead, Merck, BI, Roche
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Accidental exposure to HIV exists in the health care setting and provides a possible avenue for HIV transmission.  Like sexual exposure,
this mode of exposure is often preventable,1 but if it does occur, initiating post-exposure prophylaxis soon (within 1-2 hours optimally) after
exposure provides the best defense against HIV transmission.2 The overall HIV transmission rate for cases of occupational exposure is
estimated at approximately 0.3%.3 Exposure to blood and body fluids or tissues contaminated with blood carry a risk of transmission as
do genital secretions.  The risk of transmission for nonbloody body fluids (e.g. cerebrospinal, pericardial, amniotic) is undetermined.
Exposure to nonbloody tears, sweat, saliva, urine, vomit, or feces is not considered to pose a significant risk of HIV transmission.2 
The rationale behind PEP is that it appears to stop cellular HIV infection before the virus becomes established in cells.  In order for PEP
to be effective, then, it must be initiated before there is detectable viremia.3 The following two tables provide guidelines for provided PEP
in an occupational setting. Most often, the basic two-drug PEP regimen is the combination of zidovudine plus lamivudine, although other
combinations may be considered.2 The expanded three-drug PEP recommendation adds a PI (lopinavir), an  NRTI (abacavir), or an
NNRTI (efavirenz) to the basic regimen.2 An occupational exposure report should also accompany each incident (Table 2). 
Table 1: HIV PEP for Percutaneous Injuries2
Table 2: Information for Occupational Exposure Report2
 date and time of exposure
 details of where and how exposure occurred, including the pro-
cedure being performed at time of exposure
 details of severity of exposure (amount, type of exposure,
depth of injury, etc.)
 details of exposure source
 details of exposed person (i.e. HBV vaccination status)
 details of  PEP, counseling, and follow-up: counseling and fol-
low up should always be offered to address psychological effects
of occupational exposure.
Table 3: Situations Requiring Expert* Consultation for PEP2
 Delayed (more than 24-36 hours) exposure report
 Unknown source
 Pregnancy (known or suspected) in exposed person
 Antiretroviral resistance of source virus
 Toxicity of initial PEP regimen
*Expert: Local expert or the National Clinician’s PEP Hotline (PEPline: 1.888.448.4911)
References:
1. Proia LA, Kessler HA. 2001 Infect Med 18 (9): 428-438. Also available at
http://hiv.medscape.com
2. Centers for Disease Control and Prevention.  MMWR 2001;50 
(No. RR-11).
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Exposure Type
Less Severe4
More Severe7
1. HIV-Positive, Class 1 -- asymptomatic HIV infection or known low viral load (e.g. <1,500 RNA copies/mL). HIV-positive, Class 2
--symptomatic HIV infection, AIDS, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert
consultation, initiation of postexposure prophylaxis (PEP) should not be delayed pending expert consultation, and, because expert
consultation alone cannot substitute for face-to-face counseling, resources should be available to provide immediate evaluation
and follow-up care for all exposures.
2. Source of unknown HIV status (e.g., deceased source person with no sample available for HIV testing).
3. Unknown source (e.g., a needle from a sharps disposal container).
4. Less severe (e.g., solid needle or superficial injury).
5. The designation "consider PEP" indicates PEP is optional and should be based on an individualized decision between the
exposed person and the treating clinician.
6. If PEP is offered and taken and the source is later determined to be HIV-negative, PEP should be discontinued.
7. More severe (e.g., large-bore needle, deep puncture, visible blood on device, or needle used in patient's artery or vein).
For information on mucous membrane and non-impact skin exposures see the CDC Guidelines.
Note: Some State Departments of Health, including New York, recommend 3 drug PEP whenever PEP in indicated.
HIV+ Class 11
Recommend Basic
2 Drug PEP
Recommend
Expanded 3 Drug
PEP
HIV+ Class 21
Recommend
Expanded 3 Drug
PEP
Recommend
Expanded 3 Drug
PEP
Source of Unknown
HIV Status2
Generally, no PEP war-
ranted, however, consid-
er basic 2 drug PEP5 for
source with HIV risk 
factors6
Generally, no PEP war-
ranted, however, consid-
er basic 2 drug PEP5 for
source with HIV risk 
factors6
Unknown Source3
Generally, no PEP
warranted, however,
consider basic 2 drug
PEP5 in settings where
exposure to HIV-infect-
ed persons is likely
Generally, no PEP
warranted, however,
consider basic 2 drug
PEP5 in settings where
exposure to HIV-infect-
ed persons is likely
HIV Negative
No PEP warranted
No PEP warranted
Infection Status of Source
Spotlight: Correctional Health Care Exposure to Infectious Disease
6
Exposure prevention and postexposure pro-
phylaxis (PEP) can improve safety for cor-
rectional health care workers in a high-risk
work environment. However, a new study by
researchers at Columbia University’s
Mailman School of Public Health reveals that
correctional health care workers are being
exposed to infectious disease and may not
be doing all they can to prevent that expo-
sure.
The study, the first to focus on the practices
of correctional health care workers, was
funded by the National Institute for
Occupational Safety and Health (NIOSH).  It
surveyed correctional health care workers in
Rhode Island, Maryland and Texas – repre-
senting low, medium and high risk for expo-
sure from inmate patients. 
"We found 7 percent reporting an exposure
in the last six months. This corresponds with
our hospital data [for heath care worker
exposures.] We wouldn’t have thought they
would have had as much of a risk because
they are not doing as many procedures [as
hospitals]," said Robyn Gershon, Dr.PH,
MHS of the Mailman School of Public Health
at Columbia University.
Gershon said the research team entered the
prisons in the three states with a question-
naire for health care workers to complete
with inquiries regarding accidental expo-
sures and Hepatitis B vaccines status,
among others.
A tube of blood was drawn from consenting
health care workers and tested for Hepatitis
B antibody and antigen, and for markers of
Hepatitis C virus (HCV) infection.  In addi-
tion, a skin test was performed for the pres-
ence of TB.  Gershon said the researchers
received information from over 400 partici-
pants.
"[The inmate population] is getting older and
[there are] more acutely ill inmates. They are
pretty sickly and our health care workers are
doing a lot of intervention with them and are
[therefore] getting exposed [to infectious dis-
eases]," said Gershon.
Exposures Are Happening
The survey results revealed that 4 percent of
participants were carriers of the Hepatitis B
virus yet none of those knew their infected
status. "It is almost a public health implica-
tion," said Gershon.  Additionally, 3 percent
of participants said they were aware of a
previous positive HCV test, and in fact three
percent were HCV infected. 
In terms of types of exposure, 7 percent of
respondents said they had experienced at
least one needle stick, 4 percent had experi-
enced at least one splash to the eyes and 2
percent had been cut with sharps. Also,
according to the study, 32 percent of those
surveyed never reported an accidental expo-
sure. 
Why were they not reporting? The reason
many respondents gave is that they did not
know to whom to give the information,
Gershon reported.
But Gershon also believes that many health
care workers, who shared their feelings pri-
vately, perceive they would be penalized in
some way if they reported an accidental
exposure. "They know [what they should do]
but a lot of them are in denial," she said.
Moreover, for workers in facilities located in a
remote spot from a local hospital, seeing a
doctor may feel like too much of a burden.
Gershon explained that this under-reporting
poses a problem for prevention in correction-
al health care settings. "How can you pre-
vent it if you don’t have the data," she said.
Compliance a Problem
According to Gershon, one of the reasons for
the relatively high number of exposures is
lack of compliance with prevention mea-
sures. "There are some bad behaviors here -
this is why they are getting exposed,"
Gershon said. 
Despite improved safety measures including
requirements to use safe needles that do not
need to be recapped, some safety issues
remain. The study results reveal the follow-
ing lack of protection: 42 percent of respon-
dents lack protective clothing, 46 percent
lack eye protection, and 27 percent partici-
pate in improper sharps disposal. Beyond
that, Gershon said that in some systems
safer devices might be chosen for a whole
agency without the consultation of those who
work on the "front lines." "My understanding
is safety committees don’t always have rep-
resentation from front line workers," she
said.
Other issues mentioned by health care work-
ers included no place for a proper break,
where staff can eat and drink in a separate
area. "They don’t have stuff like that and
have to go to the cafeteria and they don’t
want to do that. They eat and drink where
they have clinic," Gershon said.
Other problems occur when these workers
do not follow up with preventative vaccines.
In the study, 55 percent of participants who
said they had received Hepatitis B vaccine
also had an observable titer. "It could mean if
[the remainder] had an exposure they would
not have a response. It is a heads up to let
them know they might want to follow up.
They are advised to consult their own practi-
tioner to get another shot," said Gershon.
For TB risk, the researchers found that only
37 percent used a mask with HEPA filter, 25
percent used surgical masks and 22 percent
used none at all. 
On the positive side, Gershon said that 50
percent of respondents had had training on
TB prevention in the last year and 97 percent
had been tested at work. However, 16 per-
cent of respondents tested positive for TB
when in the last year they had tested nega-
tive. 
So what should be done to reduce this risk
for correctional health care workers?
Gershon has some ideas.
Recommendations
A safe working environment is an important
predictor for compliance with preventative
measures. Availability of proper resources,
including small details such as making sure
workers have gloves that fit properly, can
mean the difference between compliance or
non-compliance. Agencies should be paying
attention to these details to help prevent
unnecessary exposures among employees,
said Gershon.
Additionally, Gershon suggests that officials
conduct a periodic review of employee risk.
The data might show across institutions a
pattern of exposures or a pattern of safety.
"It has to be a combination of public health
and correctional agencies doing [the review].
I think [corrections] would be wise to do it
themselves in their accreditation agencies
and create a standardized reporting pro-
gram," Gershon said. "Some facilities have
marvelous state of the art programs but
some need more direction. It would be nice if
there were more uniformity. There's certainly
room for improvement."
For more information about the study, con-
tact Gershon via email at rg405@colum-
bia.edu
Note:  OSHA mandates HEPA respirator use
and while new standards may not be neces-
sary, compliance with existing standards is.
The newly revised OSHA bloodborne
pathogen control standard requires annual
risk assessment and annual input from front
line staff.  Also, the existing OSHA 2000 log
should record all needlestick injuries, and
employee training is required to include what
to do after an exposure incident.  An employ-
er can be fined if this process is not followed
correctly. This study has revealed the need
for the implementation of an increased com-
pliance with the existing OSHA standards
within corrections. Visit www.osha.gov.
*Nothing to disclose.
By Michelle Gaseau*, Managing Editor, The Corrections Connection
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1 Summary of Antiretroviral Agents Dosing and Administration Recommendations 
by HEPP News Staff
Zidovudine
(AZT, ZDV, Retovir)
300mg bid (or with
3TC as Combivir 
1 tab bid)
None
 Bone Marrow
suppression: 
anemia and/or 
neutropenia
 subjective 
complaints: GI 
intolerance,
headache, 
insomnia, asthenia
Ribavirin may
reduce AZT
activity
Didanosine
(ddl, Videx, Videx EC)
Tablets or oral
solution
>60kg: 400mg qd
(EC) or 200mg bid
(tabs) or 250mg
bid (powder) 
<60kg: 250mg qd
or 125mg bid
(tabs) or 167mg
bid (powder)
Levels 55%
Take 1 hr before
or 1 hr after meal
 Pancreatitis
 Peripheral
neuropathy
 GI intolerance,
nausea, diarrhea
Methadone 
ddI levels 41%,
consider ddI
dose increase
Zalcitabine
(ddC, Hivid)
0.75mg tid
None
 Peripheral
neuropathy
 Stomatitis
Methadone  
ddI levels 27%.
No dose adjust-
ment
Stavudine
(d4T, Zerit)
>60kg: 40mg bid
<60kg: 30mg bid
None
Peripheral neu-
ropathy
None
Lamivudine
(3TC, Epivir)
150mg bid or
with AZT as
Combivir (1 tab
bid) <50kg:
2mg/kg bid)
None
(minimal toxicity)
None
Abacavir
(ABC, Ziagen)
300mg bid
None
Alcohol ABC
levels 41%
Hypersensativity
(2-5%), fever,
nausea, vomit-
ing, anorexia,
cough, dyspena,
malaise, morbilli-
form rash. 
May be life-
threatening with 
rechallenge.
None
Tenofovir
(Viread)
(nucleotide ana-
log) 300mg
once daily
Should be taken
with a meal
 Bone 
(in animals)
 Renal 
(in animals)
 Mild to 
moderate 
gastrointestinal:
nausea, vomit-
ing, diarrhea,
flatulence
take two hours
before or one
hour after 
didanosine 
(if applicable)
Adapted from Bartlett JG and Gallant JE.  2001-2002 Medical Management of HIV Infection.  Johns Hopkins University, Baltimore,
MD. 2001.  Additional information from http://www.gilead.com/prod_pdf/viread_pi.pdf.
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Nevirapine (Viramune)
200mg po qd x 14 days,
then 200mg po bid
None
 Induces cytochrome
P450 enzymes
 PI interactions see
Table 4-16 in Bartlett
Guide*
 Rash (15-30%) may
require hospitalization;
rare cases of Stevens-
Johnson syndrome;
hepatitis
Delavirdine (Rescriptor)
400mg po tid
None
 Methadone AUC
decreased 60% titrate
methadone dose
 Not recommended:
Ketoconazole and rifampin
 Caution: anticonvulsant
 Rash; headaches
 Increased transaminase
levels
Efavirenz (Sustiva)
600mg po qd at hs
-50% with high fat meal; avoid after high fat meal
 Inhibits and induces cytochrome P450 3A4 enzymes
 Contraindicated drugs: astemizole, midazolam, triazolam, 
cisapride, ergot alkaloids, tergenadine
 PI interactions: generally  dose when given with PIs (like
Kaletra) and see Table 4-16 in Bartlett Guide*
 Possibly important drug interactions: see Chapter 4 in Bartlett
Guide*
 Methadone AUC decreased 60% titrate methadone dose
 Dizziness, “disconnectedness,” somnolence, insomnia, bad
dreams, confusion, amnesia, agitation, hallucinations, poor 
concentration
 40% usually resolves after 2 weeks
 take hs.
 Rash- severe in 5%; rare reports of Stevens-Johnson syndrome: 
 Teratogenic in cynomalgus monkeys
 Avoid in pregnancy, and women and men should use adequate
contraception methods.
 False positive drug screening test for cannabinoids (marijuana)
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)
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HIV101 continued on page 8
Resources & Websites
Postexposure Prophylaxis Resources:
National Clinicians’ Postexposure Prophylaxis Hotline (PEPline)
This hotline is run by the University of San Francisco/San Francisco
General Hospital staff and is supported by the CDC and other govern-
ment health organizations.
Phone: 1.888.448.4911
Web: http://www.ucsf.edu/hivcntr
Needlestick!
Website to help manage and document occupation exposure to blood
and other bodily fluids.  Maintained by the University of California Los
Angeles (UCLA) Emergency Medicine Center, UCLA School of
Medicine.
http://www.needlestick.mednet.ucla.edu
CDC PEP Guidelines for HIV, HBV, and HCV
MMWR 2001; 50 (No. RR-11) on the web at
http://www.cdc.gov/mmwr/PDF/RR/RR5011.pdf
Drug Update Information
Listing of Drug-induced HIV Genome Mutations
http://www.iasusa.org/resistance_mutations/index.html
Complete Information on Kaletra
http://www.fda.gov/cder/foi/label/2000/21226lbl.pdf
Complete Information on Viread
http://www.gilead.com/prod_pdf/viread_pi.pdf
HIV Treatment Websites
AMFAR HIV/AIDS Treatment Directory, Summer 2001 Edition
For free copies, contact Barbara Good at barbara.good@amfar.org or
fax a request to 212.806.1601
Updated Adult and Adolescent HIV Treatment guidelines
http://www.hivatis.org/guidelines/adult/Aug13_01/pdf/AAAug13S.PDF
Hopkins AIDS Service: Medical Management of HIV Infection
http://hopkins-aids.edu/publications/book/book_toc.html
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Summary of Antiretroviral Agents... (continued from page 7)
Indinavir**
(Crixivan)
800mg q 8h
Separated ddI
dose by 1 hr
77%; take 1 hr
before or 2 hours
after meals; may
take with low fat
snack or skim
milk
GI intolerance
(10-15%);
nephrolithiasis or
nephrotoxicity
(10-15%);
headache;
asthenia;
dizziness; rash;
metallic taste;
ITP; alopecia;
lab: increase
indirect
bilirubinemia
(inconsequential)
Class side
effects*
Ritonavir
(Norvir)
600mg bid
Separate ddI
dose by 2 hr
15%; take with
food if possible
to improve toler-
ability
GI intolerance
(20-40%); pares-
thesias-circum-
oral and extremi-
ties (10%); taste
perversion
(10%);
lab:triglycerides
increase in 60%
and transami-
nase increase in
10-15%, CPK
and uric acid
increase Class
side effects*
(Invirase)
Not recommend-
ed as single PI
400mg bid with
RTV
No food effect
when taken with
RTV
GI intolerance
(10-20%);
increase Class
side effects*
Saquinavir**
(Fortovase)
1200mg tid
6x; take with
large meal
unless taken
with RTV
GI intolerance
(20-30%);
headache;
hypoglycermia;
transaminase
increase
Class side
effects*
Amprenavir
(Agenerase)
1200mg bid
(caps)
1400mg bid 
(oral solution)
high fat meal
decreases AUC
20%; can be
taken with or
without food, but
high fat meal
should be 
avoided.
GI intolerance
(10-30%); rash
(20-25% - usually
at 1-10 wks),
Stevens-Johnson
syndrome (1%);
paresthesias
(10-30% -
perioral or
peripheral)
Increase in liver
function tests.
Class side
effects*
Nelfinavir
(Viracept)
1250mg bid or
750mg tid
2-3x; take
with meal or
snack
Diarrhea
(10-30%)
Class side
effects*
Lopinavir +
Ritonavir
(Kaletra)
3 caps or 0.5mL
twice daily
4 caps bid
when used with
efavirenz or
nevirapine
Fat increases
AUC 50% to
80%; should be
taken with food
GI intolerance:
nausea, vomit-
ing, diarrhea
Elevated Lipids
Asthenia
Class side
effects*
PROTEASE INHIBITORS (PIs)
R
ec
om
m
en
de
d 
D
os
e
Fo
od
 E
ffe
ct
Si
de
 E
ffe
ct
s*
*For full information on toxicity and drug interactions for PIs and class side effects, see Chapter 4 of Bartlett JG and Gallant
JE.  2001-2002 Medical Management of HIV Infection.  Johns Hopkins University, Baltimore, MD. 2001.  For information on
Tenofovir, see http://www.gilead.com/prod_pdf/viread_pi.pdf.
**These two drugs usually used in combination with ritonavir (see HEPP News, February 2001).
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3rd International Hepatitis C
Update for the New Millennium
November 30-December 1, 2001
Houston, Texas
Fee: Physicians- $165; Other
Health Care Professionals- $135
Visit: www.uth.tmc.edu/cme
Email: Kristen.K.Brockman@
uth.tmc.edu
Call: 713.500.5127
CME and CEU credit available
41st Interscience Conference on
Antimicrobial Agents and
Chemotherapy
December 16-19, 2001
Chicago, Illinois
Sponsored by American Society for
Microbiology (ASM)
Visit: www.icaac.org
9th Conference on Retroviruses
and Opportunistic Infections
February 24-28, 2002
Seattle, Washington
Registration: Dec. 10, 2001-
Jan. 23, 2002
Call: 703.535.6899
Visit: www.retroconference.org
2002 National STD Prevention
Conference
March 4-7, 2002
San Diego, California
Fee: before Feb. 8: $140; 
after Feb. 8: $165
Visit: http://www.stdconference.org/
Call: Glenda Vaughn,
404.639.8260
Email: ghv1@cdc.gov
14th National HIV/AIDS Update
Conference (NAUC)
March 19-22, 2002
San Francisco, California
Sponsored by (amfAr) American
Foundation for AIDS Research
Abstract Deadline: Nov. 15, 2001
Fee: Before Dec. 15: $275; 
Dec 15-March 1: $325; 
After March 1: $375 
(special rates available)
Visit: http://www.amfar.org/cgi-
bin/iowa/nauc/index.html
CME credit available
International Conference on
Emerging Infectious Diseases
(ICEID)
March 24-27, 2002
Atlanta, Georgia
Visit: http://www.cdc.gov/iceid/
Email: cas1@cdc.gov
Save the 
Dates
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FDA Approves Tenofovir for all HIV Patients
Associated Press, 10/28/01
Tenofovir (Viread, produced by Gilead), a new
antiretroviral medication, lowered the viral load
of patients who had developed drug resistant
virus (see Newsflashes, Aug/Sept HEPP News).
The FDA has now approved the medication for
use in all HIV-positive patients (10/26/01).
Tenofovir has been shown to reduce the viral
load by as much as 75% when used in combina-
tion with other medications. Experts caution
against prescribing tenofovir for drug-naïve
patients until study results on the use of the drug
in newly diagnosed patients are released.
Tenofovir is a once-a-day pill that will cost about
$4,135 for a year’s supply.  
Genetic Test Available to Show Drug-
Resistance
Associated Press, 9/27/01
The FDA recently approved gene-based test,
Visible Genetic Inc.’s Trugene, that analyzes an
HIV patient’s viral mutations in terms of drug
resistance. This test will aid physicians in pre-
scribing the best medications for each patient
depending on his/her viral genotype. Trugene
uses a blood sample to identify all known genet-
ic mutations in the virus. It then compares the
individual’s genetic mutations to over 70 muta-
tions known to be linked to resistance to specific
drugs. The turnaround time is three days and will
cost $300-$500 per patient (see Paar D, Altice F,
HEPP News September 2000). This is the first
genotyping test to receive FDA approval. Other
genotyping tests are available from many com-
mercial suppliers including the Phenosense test
from Virologic. 
Specialists More Likely to Recommend
Appropriate Therapies
2001 July.  The AIDS Reader 11(7): 348-353.
A survey of physicians in California, Florida,
Massachusetts, and New York found that those
with less experience caring for HIV/AIDS
patients need expert advice in the process of
treating patients. The study presented physi-
cians with two hypothetical HIV/AIDS patients
and asked the physicians how they would treat
those patients.  Infectious disease specialists
were more likely to recommend treatments con-
sistent with those of the HHS and the
International AIDS society than were general
internal medicine physicians. The general
internists, however, were often aware of gaps in
their knowledge and said they would refer the
patient to a specialist.
No Mandatory HIV Testing of State Prisoners
in Indiana
Indianapolis Star, 10/24/01
Indiana DOC officials estimate that approximate-
ly 1% of state inmates are HIV positive but do not
know the exact number because Indiana does
not have a mandatory testing law for inmates.
Although a bill was passed by the state legisla-
ture last year that would require mandatory HIV
and HCV testing for all inmates, it was vetoed by
the governor for budgetary reasons.  This testing
is estimated to cost $173,285 per year.  HIV test-
ing is available to inmates upon request.
Experts recommend educating and counseling
prisoners to be voluntarily tested for HIV and
HCV.
Hepatitis
HCV Costs the U.S. $5 Billion in 1997
Arch Int Med 2001; 161 (18): 2231-2237.
A study reports that in 1997, hepatitis C cost the
U.S. approximately $5.46 billion in medical
costs, lost wages, and lost home production.
Hepatitis C is the most common blood-borne
infection in the U.S. These costs are on par with
the cost of asthma in US for the same year ($5.8
billion). There are estimates that HCV-related
mortality could triple within the next twenty years,
indicating that increased prevention, treatment,
screening, and research are necessary.
MA Canceling Hepatitis C Programs
Boston Herald, 10/5/01
The Massachusetts state legislature plans to cut
a program that teaches physicians and others at
risk for hepatitis C about the disease due to a
budget impasse. Although the Massachusetts
state senate set aside $3.9 million for the pro-
gram for fiscal year 2002 (which began on July
1, 2001) the House did not allocate any funding.
According to a policy issued by the governor’s
office, agencies are to operate on a lower bud-
get. The program provided counseling and edu-
cation for those at risk for contracting hepatitis C
and raised awareness of people who were
unaware they were infected with HCV. The cuts
will affect education programs but will have no
effect on treatment funding. Approximately
110,000 people in Massachusetts are estimated
to be infected with HCV.
Other
Syphilis on the Internet
San Francisco Chronicle, 10/26/01
Syphilis is on the rise among gay and bisexual
men. This spike in syphilis cases has been
recorded in San Francisco, San Diego, Florida,
Boston, and Chicago according to the San
Francisco Department of Public Health. The
number of syphilis cases in San Francisco near-
ly doubled from 42 in 1999 to 77 in 2000 with a
similar increase expected this year. Officials
there say 16 syphilis cases in San Francisco this
year have been linked to an internet chat room
for gay and bisexual men. Although the internet
service provider has been reluctant to post
syphilis warnings, it has given the Health
Department access to the chat room to post pre-
vention messages, an offer that has been reject-
ed as “ineffective”. Health officials view the rise
in syphilis cases as a decline in safe sex prac-
tices and a “complacency” about HIV. Syphilis
sores (like other STDs) leave a person more vul-
nerable to HIV infection.
News Flashes
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through May 31, 2002. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. What is the correct dosing for lopinavir+ritonavir (Kaletra) if NOT
using in combination with an NNRTI?
(a) 3 caps or 3mL bid
(b) 3 caps or 5mL qod
(c) 5 caps or 3mL bid
(d) 3 caps or 5mL bid
(e) 5 caps or 5 mL qod
2. In addition to Trizivir (AZT, 3TC, Abacavir), Combivir (AZT, 3TC),
and ddI EC (Enteric Coated), how many ART drugs are there?
(a) 6 NRTIs, 3 NNRTIs, 6 PIs
(b) 3 NRTIs, 6 NNRTIs, 3 PIs
(c) 4 NRTIs, 4 NNRTIs, 6 PIs
(d) 6 NRTIs, 6 NNRTIs, 3 PIs
(e) 3 NRTIs, 3 NNRTIs, 6 PIs
3. The basic two-drug PEP regimen most often consists of:
(a) one NRTI + one PI
(b) one NRTI + one NNRTI
(c) two NNRTIs
(d) two NRTIs
(e) one NNRTI + one PI
4. The expanded three-drug PEP regimen is recommend in the fol-
lowing circumstances (according to CDC guidelines):
(a) a less severe exposure to HIV-positive class 2 fluids
(b) a more severe exposure to HIV-positive class 1 fluids
(c) a less severe exposure to HIV-positive class 1 fluids
(d) a more severe exposure to HIV-positive class 2 fluids
(e) a, b, and d
5. In which of the following situations of occupational exposure
should expert consultation be sought to determine the appropriate
PEP regimen?
(a) initial PEP regimen is toxic
(b) exposure report occurs more than 36 hours after exposure
(c) source virus is resistant to antiretroviral medication
(d) the exposed person is pregnant
(e) all of the above
6. Exposure to which of the following fluids is NOT considered to
pose a significant threat for HIV infection?
(a) blood
(b) nonbloody saliva
(c) vaginal fluids
(d) semen
(e) bloody cerebrospinal fluid
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
10
CME is Now Available Online at www.hivcorrections.org
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